Table 3.
Identification of individual drug entities included within drug groups in Dutch HDFs (n = 62). The digestive tract.
| HDFs | HDFs | ||||||
|---|---|---|---|---|---|---|---|
| Drug group (ATC code) | Year* | n | (%) | Drug group (ATC code) | Year* | n | (%) |
| H2-receptor antagonists (A02BA) | 5HT3antagonists(A04AA) | ||||||
| Cimetidine+ | 1976 | 22 | (35) | None | 8 | (13) | |
| Famotidine | 1987 | 24 | (39) | Dolasetron | 1997 | 0 | (0) |
| Nizatidine | 1988 | 0 | (0) | Ondansetron | 1990 | 11 | (18) |
| Ranitidine ** | 1981 | 56 | (90) | Granisetron ** | 1991 | 38 | (61) |
| Roxatidine *** | 1986 | 0 | (0) | Tropisetron | 1992 | 11 | (18) |
| H+ pump inhibitors(A02bc) | |||||||
| Lansoprazole*** | 1992 | 1 | (2) | ||||
| Omeprazole ** | 1988 | 61 | (98) | ||||
| Pantoprazole *** | 1995 | 0 | (0) | ||||
*
Year of introduction to the pharmaceutical market
**
Recommended by national guidelines
***
Not preferred or insufficiently evaluatedby guideline authorities; Drug entities without asterisks are not considered in the national pharmacotherapeutic guidelines
+
Included in the 10th edition of the WHO EDL.